贝那普利治疗局灶节段性肾小球硬化症的疗效

Effect of Benazepril on Focal Segmental Glomerulosclerosis

目的:观察单用贝那普利及贝那普利联用激素对局灶节段性肾小球硬化症的疗效。方法:109例尿蛋白>1．0 g·d^(-1),血肌酐<133μmol·L^(-1)的局灶节段性肾小球硬化症患者随机分成单用组和联用组,单用组应用贝那普利10-30 mg·d^(-1)治疗,联用组应用贝那普利10～30 mg·d^(-1)+泼尼松1 mg·kg^(-1)·d^(-1)治疗,观察24 h尿蛋白定量,血白蛋白、胆固醇、肌酐的变化。结果:两组均能明显减少蛋白尿,治疗1月后尿蛋白即有显著下降(P<0．01)。两组尿蛋白减少差值及血肌酐比较差异无统计学意义(P>0．05)。结论:ACEI联用激素并不比单用ACEI治疗有更好的疗效,而单用ACEI可能为有效的治疗手段,又可避免激素的副作用。

Objective： To investigate the efficacy of benazepril alone and benazepril combined corticosteroide in treatment of focal regmental glomerulosclerosis. Method： One hundred and nine cases with FSGS,whose proteinuria 〉 1.0 g24 hours,and serum creatinine concentrations 〈133 μmol·L^-1,were randomly divided into two groups： benazepril group 10 -30 mg·d^-1 and the combination group（ benazepril 10 -30 mg·d^-1 combined prednisone 1 mg·kg^-1 ）. The change of proteinuria of 24 hours, serum albumin, cholesterol and creatinine were observed. Result： The combination therapy or benazepril alone after one month treatment,the levels of proteinuria decreased significantly（ P 〈 0.01 ）, while no significant differences in reduction of proteinuria were noticed between the two groups, and there were no significant elevation of serum creatinine in both groups during follow-up period. Conclusion： Adrenocorticosteroide therapy may not be beneficial in patients with FSGS. Benazepril may be a valuable therapeutic agent and avoiding serious side effects of steroid agents.